Transparency Market Research

Global Preimplantation Genetic Diagnosis Market Is Estimated to Grow at a CAGR of 6.2% from 2013 to 2018 and Reach US$47.4 Million by the End of 2018 : TMR

Preimplantation Genetic Diagnosis Market (Test Type - PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020


Albany, NY -- (SBWIRE) -- 02/02/2015 -- For the last two decades, the world of medical science has registered tremendous progress in terms of research and development of novel cures. Humans were served a plethora of medical innovations that promised a healthier lifestyle and enhanced longevity. With the aim of curing diseases and eradicating human deformities of any kind, various researches were undertaken in the last couple of years, a few of which were deemed controversial yet path-breathing. One such discovery made by medical science was the ability to avoid passing on inheritable diseases and genetic conditions to children.

Browse: global preimplantation genetic diagnosis market :

Preimplantation genetic diagnosis (PGD) in medical terms is a procedure used before implantation that helps in identifying genetic defects present within embryos created by in vitro fertilization (IVF). The procedure helps prevent certain inheritable diseases and disorders from being passed on to the progeny. The rising prevalence of genetic disorders among infants and increasing awareness among parents about PGD technique has given a significant boost to the demand for PGD along with IVF procedure. According to recently published reports, the global preimplantation genetic diagnosis market is estimated to grow at a CAGR of 6.2% from 2013 to 2018 and reach US$47.4 million by the end of 2018.

Global PGD Market Growth Trajectory :

The global market for preimplantation genetic diagnosis has been segmented into six distinct categories on the basis of the types of test. These are PGD for aneuploidy screening, PGD for single gene disorder, PGD for chromosomal aberrations, PGD for HLA typing, PGD for X-linked diseases, and PGD for gender selection. Among these segments, PGD for aneuploidy registered the highest demand in 2013 since aneuploidy can result in severe abnormalities in children. The PGD screening for aneuploidy helps reduce the possibility of transferring any chromosome abnormality. Previously, the pregnancy would be terminated in case a chromosomal abnormality was detected in the fetus. However, going for preimplantation genetic diagnosis helps parents-to-be overcome this drawback, since the screening of aneuploidy is carried out before the embryo is implanted and the child is conceived.

The global preimplantation genetic market can be segmented geographically into four categories, which are North America, Asia Pacific, Europe, and RoW (Rest of the World). These markets are further analyzed on the basis of the type of test. The increase in awareness about PGD and high number of IVF cycles conducted in the region meant that Europe registered the maximum demand for PGD and emerged as the dominant market. North America is also expected to grow at a high CAGR during the forecast period due to the rise in demand among mothers to identify the gender of the embryo, and rapidly increasing numbers of IVF cycles being performed across the region.

Get Sample Report Copy :

Emerging Market Trends and Growth Drivers :

The lifestyle followed by the present generation has come across as a major factor in increasing the demand for preimplantation genetic diagnosis. Delayed pregnancies, for instance, has resulted in higher demand for PGD among new mothers who are keen to ascertain the health of their baby. Similarly, a rise in the incidence of genetic diseases among infants and children has encouraged parents in favor of preimplantation genetic diagnosis. Other factors impacting the demand for IVF and PGD are lifestyle hazards such as smoking, pollution, and stress, which affect fertility adversely.

In spite of registering increasing demands in North America and Europe, PGD is encountering many restraints in the Asia Pacific region. Stringent government regulations and restrictions against gender selection and detection of X-linked diseases across developing region such as Africa, Latin America, and Asia Pacific have surfaced as hindrances to the growth of the PGD market. Lack of awareness among patients and inadequate healthcare facilities across the developing economies in the aforementioned regions also limit the use of PGD and IVF.

PGD Market Leaders :

Major companies dominating the global preimplantation genetic diagnosis market are Reprogenetics LLC and Reproductive Genetics Institute, Genea Ltd., Laboratory Corporation of America Holdings, Quest Diagnostics, Inc., Genesis Genetics, Illumina and PerkinElmer. The leading players in the market are working towards innovating better technologies in genetic testing and enhance their efficiency to provide better services to patients.

About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact :
Mr. Nachiket Ghumare
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Blog :